Aura Biosciences, Inc. Common Stock (AURA) Stock Price
AURAStock
$7.82+20.61%52W
Market Cap$810.97M
P/E—
PEG Ratio—
Div yield—
Beta0.41
AURA Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)45.50%
Price vs S&P 500 (4W)9.00%
VGM Score62.15
AURA Earnings Surprise History
Q2 25-0.47est. -0.47
Q3 25-0.40est. -0.47
Q4 25-0.37est. -0.43
Q1 26-0.50est. -0.40
Q2 26-0.48est. -0.38
AURA Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.17
4.17
4.17
4.17
Industry Peers — Biological Products(183)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
AURAAura Biosciences, Inc. Common Stock | — | — | B | $7.82 |
| AMGNAmgen Inc | C | C | B | $442.24 |
| GILDGilead Sciences Inc | C | B | B | $148.77 |
| MRNAModerna, Inc. Common Stock | D | C | A | $158.83 |
| ARGXargenx SE American Depositary Shares | D | A | B | $1019.49 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $211.38 |
| BIIBBiogen Inc. Common Stock | C | D | B | $220.77 |
| BNTXBioNTech SE American Depositary Share | C | C | B | $114.05 |
| NBIXNeurocrine Biosciences Inc | C | B | C | $153.37 |
| EXELExelixis Inc | C | B | B | $56.72 |
| HALOHalozyme Therapeutics, Inc. | C | B | A | $109.32 |
About Aura Biosciences, Inc. Common Stock
Aura Biosciences is a clinical-stage biotechnology company developing precision immunotherapies designed to treat solid tumors while preserving organ function. Its lead candidate, bel-sar, is in late-stage clinical trials for primary choroidal melanoma and other ocular cancers, with early-stage development in bladder cancer. The company operates exclusively in the United States.